Moderna ($MRNA) stock jumped 17% on Thursday, fueled by speculation of potential buyout talks amid concerns over declining ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.5% in the afternoon session after the stock ...

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Moderna Inc. (NASDAQ: MRNA) is down 35% in 2025, making it one of the worst-performing stocks among medical stocks and the broader market. Not surprisingly, the stock is down over 80% in the last 12 ...

Moderna, Inc. (NASDAQ:MRNA) shares are trading higher Friday after the company received Health Canada approval for the updated COVID-19 vaccine. What To Know: Health Canada authorized Moderna's ...

Discover whether Moderna or BioNTech offers better long-term investment potential as both pivot from COVID-19 to innovative ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Moderna has struggled since COVID-19 vaccine demand has shrunk. The stock has correspondingly declined, as revenue has nosedived over the last few years. The long game is clinical trials in oncology ...

In the short term, Moderna (NASDAQ: MRNA) looks like a bad bet. It's coming off of the momentum of its COVID-19 vaccine, and doesn't have a lot of new ammo ready yet to expand in new directions. I ...